Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
Public ClinicalTrials.gov record NCT06409130. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effects of NNC0194-0499 Alone and in Combination With Semaglutide, of Semaglutide Alone, and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
Study identification
- NCT ID
- NCT06409130
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 270 participants
Conditions and interventions
Conditions
Interventions
- NNC0194-0499 Drug
- Semaglutide Drug
- NNC0194-0499 placebo Drug
- Semaglutide placebo (Group A) Drug
- Cagrilintide + semaglutide Drug
- Cagrilintide Drug
- Cagrilintide placebo Drug
- Semaglutide placebo (Group B) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 20, 2024 (Actual)
- Primary completion
- Nov 21, 2025 (Actual)
- Completion
- Jan 12, 2026 (Actual)
- Last update posted
- Mar 12, 2026
2024 – 2026
United States locations
- U.S. sites
- 29
- U.S. states
- 13
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Institute for Liver Health | Chandler | Arizona | 85224 | — |
| Arizona Liver Center | Tucson | Arizona | 85712 | — |
| Del Sol Research Management, LLC | Tucson | Arizona | 85715 | — |
| OM Research LLC | Lancaster | California | 93534 | — |
| California Liver Research Institute | Pasadena | California | 91105 | — |
| Covenant Metabolic Specialists LLC | Fort Myers | Florida | 33912 | — |
| Miguel Rebollar PA | Hialeah | Florida | 33012 | — |
| UF Hlth Jacksonville | Jacksonville | Florida | 32224 | — |
| Univ of Miami/Schiff Ctr | Miami | Florida | 33136 | — |
| Covenant Metabolic Specialists LLC | University Park | Florida | 34201 | — |
| Rush University Med. Cntr | Chicago | Illinois | 60612 | — |
| Kansas Medical Clinic, PA | Topeka | Kansas | 66606 | — |
| Louisiana Research Center, LLC | Shreveport | Louisiana | 71105 | — |
| Boston Medical Center_Cary | Boston | Massachusetts | 02118 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55902 | — |
| Jubilee Clinical Research, Inc. | Las Vegas | Nevada | 89106 | — |
| DSI Research,LLC | Springboro | Ohio | 45066 | — |
| University of Pennsylvania Hospital | Philadelphia | Pennsylvania | 19104 | — |
| UPMC_Center for Liver Care | Pittsburgh | Pennsylvania | 15213 | — |
| Digestive Health Research, TN | Hermitage | Tennessee | 37076 | — |
| Texas Clinical Research Institute | Arlington | Texas | 76012 | — |
| The Liver Institute | Dallas | Texas | 75203 | — |
| South Texas Research Institute | Edinburg | Texas | 78539 | — |
| Baylor St. Luke's Medical Center | Houston | Texas | 77030 | — |
| Houston Research Institute | Houston | Texas | 77079 | — |
| Amer. Rrsch Corp-TX Liver Inst | San Antonio | Texas | 78215 | — |
| Pinnacle Clinical Research | San Antonio | Texas | 78229 | — |
| Liver Specialists of Texas | Sugar Land | Texas | 77479 | — |
| Velocity Clinical Res, Waco | Waco | Texas | 76710 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 73 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06409130, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06409130 live on ClinicalTrials.gov.